

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>OCT 28 2009</u> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,028
				Filing Date	01/27/2005
				First Named Inventor	Himanshu BRAHMBHATT
				Art Unit	1632
				Examiner Name	Anoop Kumar Singh
				Attorney Docket Number	060348-0149
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	D1	US-2004/0265994-A1	12-30-2004	BRAHMBHATT ET AL.	
	D2	US-2007/0237744-A1	10-11-2007	BRAHMBHATT ET AL.	
	D3	US-2007/0241067-A1	10-18-2007	BRAHMBHATT ET AL.	
	D4	US-2007/0298056-A1	12-27-2007	BRAHMBHATT ET AL.	
	D5	US-2008/0038296-A1	02-14-2008	BRAHMBHATT ET AL.	
	D6	US-2008/0299084-A1	12-04-2008	BRAHMBHATT ET AL.	
	D7	US-6,635,448-B2	10-21-2003	BUCCIARELLI ET AL.	
	D8	US-7,011,946-B2	03-14-2006	RAYCHAUDHURI ET AL.	
	D9	US-7,125,679-B2	10-24-2006	ASHKAR	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	D10	WO-00/63364-A2	10-26-2000	AMERICAN HOME PRODUCTS CORP.		
	D11	WO-2005/056749-A2	06-23-2005	ENGINEIC MOLECULAR DELIVERY PTY LTD.		
	D12	WO-2006/066048-A2	06-22-2006	BETH ISREAL DEACONESS MEDICAL CENTER		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	D13	Alan BRIDGE et al., "Induction of an interferon response by RNAi vectors in mammalian cells," Nature Genetics, Vol. 34, No. 3, (2003), pgs. 263-264.	
	D14	Catherine GRILLOT-COURVALIN et al., "Wild-type intracellular bacteria delivery DNA into mammalian cells," Cellular Microbiology, Vol. 4, No. 3, (2002), pgs. 177-186.	
	D15	H. BRAHMBHATT et al., U.S. PTO Notice of Allowance, Serial No. 10/602,021 dated 06-22-2009, 5 pgs.	
	D16	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 10/581,990 dated 03-19-2009, 32 pgs.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>OCT 28 2009</u> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,028
				Filing Date	01/27/2005
				First Named Inventor	Himanshu BRAHMBHATT
				Art Unit	1632
				Examiner Name	Anoop Kumar Singh
				Attorney Docket Number	060348-0149
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	D17	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 10/602,021 dated 05-04-2006, 10 pgs.		
	D18	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 10/602,021 dated 05-15-2007, 10 pgs.		
	D19	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 10/602,021 dated 07-25-2008, 10 pgs.		
	D20	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 11/211,098 dated 02-24-2009, 24 pgs.		
	D21	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 11/211,098 dated 04-24-2008, 38 pgs.		
	D22	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 11/211,098 dated 08-07-2009, 23 pgs.		
	D23	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 11/691,698 dated 12-24-2008, 13 pgs.		
	D24	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 11/765,635 dated 10-06-2009, 40 pgs.		
	D25	H. BRAHMBHATT et al., U.S. PTO Office Action, Serial No. 12/053,197 dated 08-25-2009, 25 pgs.		
	D26	Hao WU et al., "Small Interfering RNA-induced Suppression of MDRI (P-Glycoprotein) Restores Sensitivity to Multidrug-resistant Cancer Cells," Cancer Research, Vol. 63, April 1, 2003, pgs. 1515-1519.		
	D27	Ian TOMLINSON et al., "Methods for Generating Multivalent and Bispecific Antibody Fragments," Methods in Enzymology, Vol. 326, (2000), pgs. 461-479.		
	D28	Inder M. VERMA et al., "Gene Therapy: Twenty-First Century Medicine," Annu. Rev. Biochem., Vol. 74, (2005), pgs. 711-738.		
	D29	J. H. HONG et al., "Antisense Bc12 oligonucleotide in cisplatin-resistant bladder cancer cell lines," BJU International, Vol. 90, (2002), pgs. 113-117.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: _____ (use as many sheets as necessary)		Application Number	10/588,028
		Filing Date	01/27/2005
		First Named Inventor	Himanshu BRAHMBHATT
		Art Unit	1632
		Examiner Name	Anoop Kumar Singh
Sheet	3	of	3
		Attorney Docket Number	060348-0149

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	D30	Jean-Remi BERTRAND et al., "Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo," Biochemical and Biophysical Research Communications, Vol. 296, (2002), pgs. 1000-1004.	
	D31	L. R. KELLAND, "Of mice and men": values and liabilities of the athymic nude mouse model in anticancer drug development," European Journal of Cancer, Vol. 40, (2004), pgs. 827-836.	
	D32	Leoni A. KUNZ-SCHUGHART et al., "The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model," Journal of Biomolecular Screening, Vol. 9, (2004), pgs. 273-285.	
	D33	Michael J. MCCLUSKIE et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates," Molecular Medicine, Vol. 5, (1999), pgs. 287-300.	
	D34	Michele CARBONE et al., "Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen?," Seminars in Cancer Biology, Vol. 14, (2004) pgs. 399-405.	
	D35	Michele DE PALMA et al., "In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors," Human Gene Therapy, Vol. 14, August 10, 2003, pgs. 1193-1206.	
	D36	Robert S. KERBEL, "What is the optimal rodent model for anti-tumor drug testing?," Cancer and Metastasis Reviews, Vol. 17, (1999), pgs. 301-304.	
	D37	Stephen L. ECK et al., "Gene-Based Therapy," Chapter 5, Goodman & Gilman's The Pharmacological Basis of Therapeutics, (1996), pgs. 77-102.	
	D38	Yi LU et al., "Delivery of adenoviral vectors to the prostate for gene therapy," Cancer Gene Therapy, Vol. 6, No. 1, (1999), pgs. 64-72.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.